phosphorylcholine has been researched along with Disease Exacerbation in 20 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-one patients with advanced neoplasms were treated with monthly cycles of perifosine loading doses of 300, 600, 900, 1,200 and 1,500 mg (dose levels 1 through 5, respectively) on days 1-2 depending on the actual dose of the initial cycle." | 9.19 | A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. ( Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A, 2014) |
| "BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins." | 9.12 | A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. ( Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R, 2006) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 5.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| "Thirty-one patients with advanced neoplasms were treated with monthly cycles of perifosine loading doses of 300, 600, 900, 1,200 and 1,500 mg (dose levels 1 through 5, respectively) on days 1-2 depending on the actual dose of the initial cycle." | 5.19 | A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. ( Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A, 2014) |
| "BACKGROUND/PATIENTS AND METHODS: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins." | 5.12 | A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. ( Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R, 2006) |
| "Treatment with perifosine was complicated by fatigue and gastrointestinal toxicity." | 2.71 | A phase II study of perifosine in androgen independent prostate cancer. ( Arlen, PM; Chen, C; Chung, EJ; Dahut, WL; Daniels, A; Figg, WD; Gulley, J; Jones, E; Lee, MJ; Parnes, HL; Posadas, EM; Sparreboom, A; Steinberg, SM; Trepel, JB; Trout, A; Wright, J, 2005) |
| "Patients with liver cirrhosis of different aetiologies are at a risk to develop HCC." | 2.66 | Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. ( Aslanidis, C; Buechler, C, 2020) |
| "Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer." | 2.50 | Topical agents and dressings for fungating wounds. ( Adderley, UJ; Holt, IG, 2014) |
| "Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer." | 2.44 | Topical agents and dressings for fungating wounds. ( Adderley, U; Smith, R, 2007) |
| "The treatment with miltefosine demonstrated significantly lower subcutaneous lesion areas compared to the control group but was not sufficient for the complete remission of the lesions." | 1.56 | Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. ( Alves, SH; de Andrade, CM; de Jesus, FPK; Engelmann, AM; Kommers, GD; Loreto, ES; Santurio, JM; Silva, TM; Tondolo, JSM; Zanette, RA, 2020) |
| "The pancreatic cancer has extremely low overall 5-year survival, and gemcitabine is the only approved single agent for pancreatic cancer treatment." | 1.40 | Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. ( Chen, B; Cheng, L; Hong, DF; Shen, XD; Xin, Y, 2014) |
| "Perifosine is a bioavailable alkylphospholipid exhibiting antitumor activity in a series of cancer types." | 1.39 | Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. ( Guo, R; Liang, S; Liu, D; Wang, X; Xu, H; Xu, Z; Yang, L; Zhang, Z, 2013) |
| "We studied whether carotid atherosclerosis, RA disease measures, or potential cardiovascular biomarkers influenced the incidence of CVD in an RA inception cohort." | 1.38 | Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study. ( Ajeganova, S; de Faire, U; Frostegård, J; Hafström, I; Jogestrand, T, 2012) |
| "Breast cancer is still one of the most important tumors among women in industrialized countries." | 1.32 | Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. ( Báñez-Coronel, M; Gutiérrez, R; Lacal, JC; Megías, D; Olmeda, D; Ramírez de Molina, A; Rodríguez-González, A, 2004) |
| "Infantile hydrocephalus is most often caused by an obstruction in the cerebrospinal fluid flow pathway and results in ventricular dilatation and chronic trauma to the surrounding brain." | 1.30 | Progressive changes in cortical metabolites at three stages of infantile hydrocephalus studied by in vitro NMR spectroscopy. ( Andersohn, RW; Harris, NG; Jones, HC; Rocca, JR, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loreto, ES | 1 |
| Tondolo, JSM | 1 |
| de Jesus, FPK | 1 |
| Engelmann, AM | 1 |
| de Andrade, CM | 1 |
| Santurio, JM | 1 |
| Zanette, RA | 1 |
| Kommers, GD | 1 |
| Silva, TM | 1 |
| Alves, SH | 1 |
| Buechler, C | 1 |
| Aslanidis, C | 1 |
| Que, X | 1 |
| Hung, MY | 1 |
| Yeang, C | 1 |
| Gonen, A | 1 |
| Prohaska, TA | 1 |
| Sun, X | 1 |
| Diehl, C | 1 |
| Määttä, A | 1 |
| Gaddis, DE | 1 |
| Bowden, K | 1 |
| Pattison, J | 1 |
| MacDonald, JG | 1 |
| Ylä-Herttuala, S | 1 |
| Mellon, PL | 1 |
| Hedrick, CC | 1 |
| Ley, K | 1 |
| Miller, YI | 1 |
| Glass, CK | 1 |
| Peterson, KL | 1 |
| Binder, CJ | 1 |
| Tsimikas, S | 1 |
| Witztum, JL | 1 |
| Liang, S | 1 |
| Guo, R | 1 |
| Zhang, Z | 1 |
| Liu, D | 1 |
| Xu, H | 1 |
| Xu, Z | 1 |
| Wang, X | 1 |
| Yang, L | 1 |
| Xin, Y | 1 |
| Shen, XD | 1 |
| Cheng, L | 1 |
| Hong, DF | 1 |
| Chen, B | 1 |
| Adderley, UJ | 1 |
| Holt, IG | 1 |
| Gigante, B | 1 |
| Leander, K | 1 |
| Vikström, M | 1 |
| Baldassarre, D | 1 |
| Veglia, F | 1 |
| Strawbridge, RJ | 1 |
| McLeod, O | 1 |
| Gertow, K | 1 |
| Sennblad, B | 1 |
| Shah, S | 1 |
| Zabaneh, D | 1 |
| Humphries, SE | 1 |
| Kauhanen, J | 1 |
| Rauramaa, R | 1 |
| Smit, AJ | 1 |
| Mannarino, E | 1 |
| Giral, P | 1 |
| Tremoli, E | 1 |
| Hamsten, A | 1 |
| Frostegård, J | 2 |
| de Faire, U | 2 |
| Figg, WD | 2 |
| Monga, M | 1 |
| Headlee, D | 1 |
| Shah, A | 1 |
| Chau, CH | 1 |
| Peer, C | 1 |
| Messman, R | 1 |
| Elsayed, YA | 1 |
| Murgo, AJ | 1 |
| Melillo, G | 1 |
| Ryan, QC | 1 |
| Kalnitskiy, M | 1 |
| Senderowicz, AM | 1 |
| Hollingshead, M | 1 |
| Arbuck, SG | 1 |
| Sausville, EA | 1 |
| Mukhopadhyay, D | 1 |
| Mukherjee, S | 1 |
| Ghosh, S | 1 |
| Roy, S | 1 |
| Saha, B | 1 |
| Das, NK | 1 |
| Chatterjee, M | 1 |
| Keenan, JD | 1 |
| Fram, NR | 1 |
| McLeod, SD | 1 |
| Strauss, EC | 1 |
| Margolis, TP | 1 |
| Ajeganova, S | 1 |
| Jogestrand, T | 1 |
| Hafström, I | 1 |
| Cho, DC | 1 |
| Hutson, TE | 1 |
| Samlowski, W | 1 |
| Sportelli, P | 1 |
| Somer, B | 1 |
| Richards, P | 1 |
| Sosman, JA | 1 |
| Puzanov, I | 1 |
| Michaelson, MD | 1 |
| Flaherty, KT | 1 |
| Figlin, RA | 1 |
| Vogelzang, NJ | 1 |
| Richman, EL | 1 |
| Kenfield, SA | 1 |
| Stampfer, MJ | 1 |
| Giovannucci, EL | 1 |
| Zeisel, SH | 1 |
| Willett, WC | 1 |
| Chan, JM | 1 |
| Ramírez de Molina, A | 1 |
| Báñez-Coronel, M | 1 |
| Gutiérrez, R | 1 |
| Rodríguez-González, A | 1 |
| Olmeda, D | 1 |
| Megías, D | 1 |
| Lacal, JC | 1 |
| Posadas, EM | 1 |
| Gulley, J | 1 |
| Arlen, PM | 1 |
| Trout, A | 1 |
| Parnes, HL | 1 |
| Wright, J | 1 |
| Lee, MJ | 1 |
| Chung, EJ | 1 |
| Trepel, JB | 1 |
| Sparreboom, A | 1 |
| Chen, C | 1 |
| Jones, E | 1 |
| Steinberg, SM | 1 |
| Daniels, A | 1 |
| Dahut, WL | 1 |
| Iorio, E | 1 |
| Mezzanzanica, D | 1 |
| Alberti, P | 1 |
| Spadaro, F | 1 |
| Ramoni, C | 1 |
| D'Ascenzo, S | 1 |
| Millimaggi, D | 1 |
| Pavan, A | 1 |
| Dolo, V | 1 |
| Canevari, S | 1 |
| Podo, F | 1 |
| Knowling, M | 1 |
| Blackstein, M | 1 |
| Tozer, R | 1 |
| Bramwell, V | 1 |
| Dancey, J | 1 |
| Dore, N | 1 |
| Matthews, S | 1 |
| Eisenhauer, E | 1 |
| Marsh, Rde W | 1 |
| Rocha Lima, CM | 1 |
| Levy, DE | 1 |
| Mitchell, EP | 1 |
| Rowland, KM | 1 |
| Benson, AB | 1 |
| Adderley, U | 1 |
| Smith, R | 1 |
| Jones, HC | 1 |
| Harris, NG | 1 |
| Rocca, JR | 1 |
| Andersohn, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial Of Oral Perifosine In Patients With Metastatic Androgen Independent Prostate Cancer[NCT00060437] | Phase 2 | 0 participants | Interventional | 2003-10-31 | Completed | ||
| Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas[NCT00644072] | Phase 1 | 33 participants (Actual) | Interventional | 2008-03-07 | Completed | ||
| A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma[NCT00053794] | Phase 2 | 17 participants (Actual) | Interventional | 2003-06-09 | Completed | ||
| Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma[NCT00059982] | Phase 2 | 0 participants | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phosphorylcholine and Disease Exacerbation
| Article | Year |
|---|---|
Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Prolif | 2020 |
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Fema | 2014 |
Topical agents and dressings for fungating wounds.
Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Biological Dressings; Disease Progression; Fema | 2007 |
5 trials available for phosphorylcholine and Disease Exacerbation
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Area Under Curve; Diarrhea; Disease | 2014 |
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Huma | 2012 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration | 2005 |
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Canada; Disease Progression; Female; H | 2006 |
A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antiemetics; Child; Disease Progression; Drug Administra | 2007 |
12 other studies available for phosphorylcholine and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits.
Topics: Animals; Antifungal Agents; Dermatomycoses; Disease Models, Animal; Disease Progression; Dose-Respon | 2020 |
Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.
Topics: Animals; Aortic Valve Stenosis; Apoptosis; Atherosclerosis; Cholesterol; Disease Progression; Fatty | 2018 |
Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Pro | 2013 |
Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Pr | 2014 |
Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men.
Topics: Age Factors; Aged; Anthropometry; Antibodies, Antiphospholipid; Antibody Specificity; Autoantigens; | 2014 |
A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Topics: Adolescent; Adult; Amphotericin B; Antibodies, Protozoan; Antimony Sodium Gluconate; Antiprotozoal A | 2016 |
Perifosine-related rapidly progressive corneal ring infiltrate.
Topics: Corneal Opacity; Disease Progression; Female; Humans; Keratoplasty, Penetrating; Middle Aged; Phosph | 2010 |
Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study.
Topics: Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid | 2012 |
Choline intake and risk of lethal prostate cancer: incidence and survival.
Topics: Adult; Aged; Betaine; Choline; Cohort Studies; Diet; Disease Progression; Follow-Up Studies; Health | 2012 |
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Topics: Animals; Breast Neoplasms; Cell Division; Choline Kinase; Disease Progression; Enzyme Activation; En | 2004 |
Alterations of choline phospholipid metabolism in ovarian tumor progression.
Topics: Carbon Radioisotopes; Cell Line, Tumor; Choline; Choline Kinase; Disease Progression; Female; Humans | 2005 |
Progressive changes in cortical metabolites at three stages of infantile hydrocephalus studied by in vitro NMR spectroscopy.
Topics: Age Factors; Amino Acids; Analysis of Variance; Animals; Aspartic Acid; Case-Control Studies; Cell M | 1997 |